|1.||Holers, V Michael: 8 articles (01/2014 - 12/2004)|
|2.||Tomlinson, Stephen: 5 articles (06/2012 - 09/2005)|
|3.||Blom, Anna M: 2 articles (09/2014 - 03/2003)|
|4.||Kulik, Liudmila: 2 articles (01/2014 - 03/2009)|
|5.||Banda, Nirmal K: 2 articles (01/2013 - 11/2009)|
|6.||Risitano, Antonio M: 2 articles (01/2013 - 06/2012)|
|7.||Qiao, Fei: 2 articles (06/2012 - 09/2005)|
|8.||Atkinson, Carl: 2 articles (06/2012 - 09/2005)|
|9.||Thurman, Joshua M: 2 articles (01/2012 - 11/2009)|
|10.||Fleming, Sherry D: 2 articles (02/2011 - 12/2004)|
06/01/1994 - "Because the tumor cells were positive for the EB virus and CD21 antigen, EB virus seemed to have infected CD21-positive NK cells and transformed them. "
10/01/1993 - "In normal and tumor cells of B lineage, CD38 was found to be also associated with surface Ig (sIg) and with the complement receptor 2 (CR2)/CD19 complex. "
09/01/1992 - "Infusion of murine monoclonal antibodies specific for human B cell membrane antigens CD21, CD24, and CD23 was effective in 80% of animals, against two of the three cell lines preventing tumor development or inducing remission according to the time of treatment. "
01/01/1998 - "Then, the investigation of CD21 expression was performed only in the EBV-positive tumors with immunohistochemical method for CD21 antigen on paraffin sections. "
03/01/1982 - "Tumor promoter 12-O-tetradecanoylphorbol 13-acetate: effect on complement and Epstein-Barr virus receptors in human lymphoblastoid cell lines."
01/01/2013 - "More intriguingly, a human fusion protein consisting of the iC3b/ C3d-binding region of complement receptor 2 and of the inhibitory domain of the CAP regulator factor H has been recently shown effective in inhibiting, in vitro, both intravascular hemolysis of and surface C3-deposition on PNH erythrocytes, and is now under investigation in phase 1 clinical trials."
06/28/2012 - "The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment."
|4.||Closed Head Injuries
03/01/2015 - "Association of complement receptor 2 polymorphisms with innate resistance to HIV-1 infection."
05/01/2014 - "Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection."
01/01/1997 - "The effect of RSV infection on the expression of B cell antigens CD21 and CD23, putative participants in Th2 responses, was investigated. "
05/01/1990 - "Complement receptor 2 mediates enhancement of human immunodeficiency virus 1 infection in Epstein-Barr virus-carrying B cells."
01/01/1992 - "While expression of complement receptor 2 (CR2) (CD21) on some CD4+ cell lines renders them more susceptible to infection by complement-treated human immunodeficiency virus (HIV), coexpression of CR2 and CD4 on peripheral blood lymphocytes has not, until recently, been observed. "
|1.||Complement Factor H (Factor H)
|2.||Complement C3b (C3bi)
|4.||Complement System Proteins (Complement)
|7.||Membrane Proteins (Integral Membrane Proteins)
|8.||DNA (Deoxyribonucleic Acid)